Biotech Values

[ThomasS]

MNTA: As expected, from the Sandoz brief (for anyone who expected a slow ramp):

"The Sandoz generic has been on the market for two full weeks, a lifetime when it comes to the introduction of a new generic; over 5 million units have been shipped around the country and are being used with patients as a more affordable equivalent to Lovenox."

{For those of you inclined to estimate full-year 2011 revs, consider that MNTA will have paid back NVS all development costs after @ Mar-Apr 2011. Thus, if MNTA continues to enjoy sole generic status, FY2011 will almost be a full year of unencumbered revs (say 70-75%) from NVS/Sandoz. Craig Wheeler stated that they would pay back within 3 quarters.}